In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genzyme, Cell Genesys merger terminated

Executive Summary

Genzyme General is buying Cell Genesys (gene therapy) for $350mm worth of Genzyme common stock. The acquisition values each Cell Genesys share at $10, a (pr)26% premium to its 10-day trailing average, and should close in the first quarter of next year. The agreement includes a collar: the exchange ratio will not be greater than 0.317 or less than 0.181 Genzyme share.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies